FDA has granted accelerated approval to Viltepso (viltolarsen) injection for the treatment of Duchenne muscular dystrophy in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.
Read more: FDA Approves Targeted Treatment for Rare Duchenne Muscular Dystrophy Mutation